https://www.fiercebiotech.com/biotech/celcuitys-breast-cancer-combo-hits-primary-endpoints-teeing-fda-filing
0
0
62 words
0
Comments
A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for success to tee up a filing for FDA approval in the fourth quarte | A phase 3 trial of Celcuity’s breast cancer combination has hit its p…
You are the first to view
Create an account or login to join the discussion